Business Wire

Synteract Adds to Leadership Team with Rare and Orphan Disease Experts Lisa Dilworth and Elisabeth Schrader

Del

Synteract, an innovative contract research organization (CRO) enabling biopharma companies to bring new medicines to market, has added two experienced members to enhance its Rare and Orphan Diseases Center of Development. Lisa Dilworth joins as vice president, rare and orphan diseases, and Elisabeth Schrader as executive director, program strategy, pediatrics and rare diseases.

Synteract has a long history of providing rare and orphan clinical trial expertise, across all phases of drug development, with more than 136 trials performed in the last five years across 50+ indications. It specializes in studies for diseases that affect a small portion of the population, where it applies its considerable operational acumen to studies that have never been done before.

“Studies for diseases that affect a small portion of the population have been a mainstay of Synteract’s for many years. With extensive and varied backgrounds in rare and orphan drug development, Lisa and Elisabeth are excellent additions to our development center,” said Steve Powell, CEO of Synteract. “Trials in this rapidly developing area come with their own unique set of challenges, particularly in components like recruitment and the high variability in global consensus on the standard of care. Our customers will greatly benefit from Lisa’s and Elisabeth’s strategic knowledge, delivery expertise, and long-standing relationships with sites and advocacy groups to address these needs. We are excited to welcome them to the team.”

Lisa Dilworth combines 18 years in study design, eligibility criteria, and overall program strategy with her prior work experience in clinical settings to bring a patient-focused mindset and strong relationships with advocacy groups to the team. She will provide leadership in rare and orphan diseases that span various therapeutic areas and specialties, including neurology, metabolic and endocrine, ophthalmology, oncology, hepatology, and others. Dilworth was previously director of therapeutic expertise, scientific affairs and rare disease at PRA Health Sciences and has held managerial roles at UCB and Chiltern International. She holds a bachelor’s degree in Integrative Biology from University of California, Berkeley and a master’s degree in Clinical Research from University of California, San Diego. She volunteers as a consultant, committee member, and speaker for the Myasthenia Gravis Foundation of America, Inc., and as consultant, advocate, and content contributor to Project Muscular Dystrophy.

Elisabeth Schrader has 20+ years of clinical research experience working in large, mid-size, and small CROs developing partnerships, delivery models, population and indication-specific operational delivery study strategies and training programs, and relationships with advocacy groups and global site networks. She will work closely with Synteract’s centers of development heads and customers in developing operational strategies for pediatric and rare disease programs as well as providing training and oversight to the project teams focused in these specialized areas of clinical focus. Schrader joins from Syneos where she was executive director, clinical development and a member of the Rare Disease Consortium and on the leadership team of the Pediatric Consortium. Prior to that she was senior customer operations director at IQVIA supporting customers with a rare disease and pediatric focus as well as leader in the Pediatric Center of Excellence. She holds a bachelor’s degree in Health Policy and Administration from University of North Carolina at Chapel Hill.

About Synteract

With 800 staff members across 21 countries, Synteract is an innovative, full-service contract research organization supporting biopharmaceutical companies in all phases of clinical development to help bring new medicines to market. Synteract has conducted nearly 4,000 studies on six continents and in more than 60 countries, working with more than 26,000 investigative sites and nearly 750,000 patients. It has contributed to more than 240 product approvals. The CRO offers a notable depth of expertise in oncology, dermatology, and neuro degenerative indications, as well as rare and orphan, pediatric, and immunotherapy studies. Connect on LinkedIn and Twitter.

Contact information

for Synteract
Hilary McCarthy, 508-829-2543
hilary@clearpointagency.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

beqom Study Shows U.S., UK Employees Aware of Gender Wage Gaps but Not of Actions Taken by Employers or Governments to Close Them19.6.2019 11:00:00 CESTPressemelding

Despite three in four workers (75%) saying they are aware of gender pay gaps existing in their country, nearly one in five (19%) admit they are not aware. More U.S. workers (21%) are unaware of gender pay gaps than UK workers (17%); among age groups, Millennials (24%) are the most unaware, compared to 16% of Gen Zs and 11% of Baby Boomers. These findings are according to beqom’s The Gender Pay Gap: What Your Employees Really Think report, which assesses enterprise worker perception on progress made in the last year to improve the gender pay gap in the U.S. and UK and aims to uncover employee perceptions about pay and identify areas for improvement. When it comes to preventing or closing pay gaps, employees believe the U.S. significantly trails the UK, with nearly one-third of UK workers (32%) saying their employer has announced a commitment to solve the pay gap compared to 13% of U.S. workers. Additionally, more UK workers (18%) say their employer has adjusted salaries for female emplo

Geri Horner Test Drives RockStar Suites aboard Virgin Voyages’ Scarlet Lady19.6.2019 11:00:00 CESTPressemelding

Virgin Voyages is upping the game for its top suites aboard the highly anticipated Scarlet Lady, with new offerings to ensure that Mega RockStars won’t have to worry about a thing during their voyage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005107/en/ Geri Horner of the Spice Girls testing out Virgin Voyages Mega Rockstar Suites in New Video (Photo: Business Wire) Geri Horner Test Drives RockStar Suites In celebration of the expanded offerings, the brand has today released exclusive video content of the suites, which features Virgin Group founder, Sir Richard Branson, and legendary British pop star, Geri Horner, of the hugely successful girl group, the Spice Girls. The video documents Horner test driving the Virgin Voyages ‘Gorgeous Suite,’ one of the ship’s most glamorous cabins, as a favor to her longtime friend, Branson. Following Horner’s journey through the suite, the footage chronicles her full RockStar ex

Moon-Walking Mini-Breaks, 3D-Printed Room Service and Hyper-Personalised Spaces: Welcome to the Hotel of 211919.6.2019 10:05:00 CESTPressemelding

Intergalactic getaways, fast-food nutrient pills, 2-3 hour working days and adaptable, personalised rooms that can transport guests everywhere from jungles to mountain ranges; in celebration of its 100th anniversary, today Hilton (NYSE: HLT) predicts the future trends set to dominate the travel and hospitality industry in the next 100 years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005341/en/ Autonomous shooting travel pods will drop guests off at mesmerising destinations, while miniature eco-systems protected from the elements by bubble-like structures will mirror their surroundings (Photo: Business Wire) In a report supported by expert insight from the fields of sustainability, innovation, design, human relations and nutrition, findings reveal how the growing sophistication of technology and climate change will impact the hotel industry in the future. Key predictions for the hotel of the future include: Persona

Japan’s MHLW Approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD AML. Expands Use to Include Specimens Collected in EDTA19.6.2019 10:00:00 CESTPressemelding

Invivoscribe is pleased to announce that on June 5th the Ministry of Health, Labor and Welfare (MHLW) approved our LeukoStrat® CDx FLT3 Mutation Assay as the companion diagnostic for Daiichi Sankyo’s Quizartinib for the treatment of FLT3-ITD positive relapse/ refractory acute myeloid leukemia (AML) patients in Japan. At the same time the Japanese MHLW added approval in use of EDTA collection tubes to the existing approval of heparin collection tubes used with this assay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005222/en/ Invivoscribe Headquarters - San Diego, CA (Photo: Business Wire) The QuANTUM-R study demonstrated that quizartinib resulted in a statistically significant improvement in overall survival (OS) compared to salvage chemotherapy when patients were selected with the LeukoStrat CDx FLT3 Mutation Assay. Mutations in the FLT3 gene are among the most important driver mutations in AML. This milestone furt

BearingPoint Acquires Public Services Consultancy Prederi in the UK19.6.2019 08:50:00 CESTPressemelding

Management and technology consultancy BearingPoint made a strategic move by acquiring Prederi, a leading consultancy focused on public services in the UK. The acquisition supports BearingPoint’s overall growth objectives, strengthens its presence in the UK, and broadens its public service capabilities. With this transaction, two highly profitable companies join forces. Prederi provides expert advice and consultancy and serves a large number of prestigious UK public sector clients. For many years, Prederi has been generating stable revenue streams. The Prederi team now expands BearingPoint’s expertise and capabilities in one of the largest and most competitive public services markets in Europe. “With the acquisition of Prederi we are continuing our growth strategy in selected markets with consultancies that are highly focused and strongly differentiated,” said Kiumars Hamidian, Managing Partner of BearingPoint. “Prederi's portfolio is a perfect complement to our public service strategy

HCL Technologies Selected by Cricket Australia as Digital Technology Partner19.6.2019 07:52:00 CESTPressemelding

HCL Technologies (HCL) and Cricket Australia (CA) have today announced a multi-year partnership, with HCL being chosen as the Digital Technology Partner of CA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005284/en/ HCL Technologies and Cricket Australia exchanging mementos to announce digital partnership. Standing left to right: Brad Hodge, former Australian international cricketer, & current cricket coach; Arthur Fillip, Executive Vice President - Sales Transformation & Marketing; Kevin Roberts, CEO, Cricket Australia; Swapan Johri, Corporate Vice President & Head - Asia/Pacific & Middle East Business; Belinda Clarke, Executive General Manager, Community Cricket & former captain of the Australian Women's Cricket Team (Photo: Business Wire) HCL, a leading global technology company, will help the Australian cricket’s governing body provide an elevated and immersive digital experience to cricket fans, players, partner